4.6 Article

NGF Upregulates the Plasminogen Activation Inhibitor-1 in Neurons via the Calcineurin/NFAT Pathway and the Down Syndrome-Related Proteins DYRK1A and RCAN1 Attenuate This Effect

期刊

PLOS ONE
卷 8, 期 6, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0067470

关键词

-

资金

  1. Alexander von Humboldt Stiftung, Germany
  2. Jerome Lejeune Foundation, France
  3. Spanish Ministry of Science and Innovation [SAF2010-16427]
  4. European Union [PS09102673]
  5. Friedrich-Naumann-Foundation, Germany

向作者/读者索取更多资源

Background: Plasminogen activator inhibitor 1 (PAI-1) is a key regulator of the plasminogen activation system. Although several lines of evidence support a significant role of PAI-1 in the brain, the regulation of its expression in neurons is poorly understood. In the present study we tested the hypothesis that NGF induces the upregulation of PAI-1 via the calcineurin/nuclear factor of activated T cells (NFAT) pathway and analysed whether the overexpression of the Down syndrome-related proteins DYRK1A and RCAN1 modulated the effect of NGF on PAI-1 expression. Results: NGF upregulated PAI-1 mRNA levels in primary mouse hippocampal neurons cultured for 3 days in vitro and in the rat pheochromocytoma cell line PC12. Reporter gene assays revealed that NGF activated the calcineurin/NFAT pathway in PC12 cells. Induction of PAI-1 by NGF was sensitive to the calcineurin inhibitor FK506 and the specific inhibition of NFAT activation by the cell permeable VIVIT peptide. Activation of calcineurin/NFAT signalling through other stimuli resulted in a much weaker induction of PAI-1 expression, suggesting that other NGF-induced pathways are involved in PAI-1 upregulation. Overexpression of either DYRK1A or RCAN1 negatively regulated NFAT-dependent transcriptional activity and reduced the upregulation of PAI-1 levels by NGF. Conclusion: The present results show that the calcineurin/NFAT pathway mediates the upregulation of PAI-1 by NGF. The negative effect of DYRK1A and RCAN1 overexpression on NGF signal transduction in neural cells may contribute to the altered neurodevelopment and brain function in Down syndrome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects

Yasmeen T. AlNajjar, Moustafa Gabr, Ahmed K. ElHady, Mohamed Salah, Gerrit Wilms, Ashraf H. Abadi, Walter Becker, Mohammad Abdel-Halim, Matthias Engel

Summary: The study found that dual inhibitors with higher selectivity for Dyrk1A and inhibition of alpha-synuclein aggregation present a potential novel therapeutic strategy for Parkinson's disease. Compound b27, displaying the highest inhibitory potency and selectivity, could be a promising drug candidate for PD treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Review Clinical Neurology

Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review

Claudia Pisanu, Giovanni Severino, Ilario De Toma, Mara Dierssen, Paolo Fusar-Poli, Massimo Gennarelli, Pietro Lio, Elisabetta Maffioletti, Eduard Maron, Divya Mehta, Alessandra Minelli, Marie-Claude Potier, Alessandro Serretti, David Stacey, Roos van Westrhenen, Laura Xicota, Bernhard T. Baune, Alessio Squassina

Summary: The study focused on investigating the expression levels of genes involved in drug disposition and action in tissues of pharmacological importance in patients treated with psychotropic drugs. Promising findings include the role of genes in inflammation, neurotransmission, and mitochondrial function. However, studies on antipsychotics or mood stabilizers often had smaller sample sizes and lacked replication compared to studies on antidepressants.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Article Clinical Neurology

Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders

Laura Xicota, Ilario De Toma, Elisabetta Maffioletti, Claudia Pisanu, Alessio Squassina, Bernhard T. Baune, Marie Claude Potier, David Stacey, Mara Dierssen

Summary: Pharmacotranscriptomics is a promising field that utilizes transcriptomic studies to predict treatment response in neurological and psychiatric disorders. This review provides an overview of the biological foundations, methodological approaches, and potential markers and sources of RNA in pharmacotranscriptomic studies. It also discusses the suitability and indications of different techniques and provides recommendations for future directions.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Article Multidisciplinary Sciences

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B

Marco Papenfuss, Svenja Luetzow, Gerrit Wilms, Aaron Babendreyer, Maren Flasshoff, Conrad Kunick, Walter Becker

Summary: This study reveals the differences between two closely related protein kinases during initial folding and as mature kinases. DYRK1B has a weaker capacity for autonomous maturation compared to DYRK1A in a bacterial expression system. This difference is mainly attributed to the divergent sequences of the C-terminal lobes of the catalytic domain. Additionally, the mature kinase domain of DYRK1B shows lower thermal stability than that of DYRK1A under heat challenge.

SCIENTIFIC REPORTS (2022)

Article Medicine, General & Internal

Multimodal in vivo Imaging of the Integrated Postnatal Development of Brain and Skull and Its Co-modulation With Neurodevelopment in a Down Syndrome Mouse Model

Sergi Llambrich, Ruben Gonzalez, Julia Albaiges, Jens Wouters, Fopke Marain, Uwe Himmelreich, James Sharpe, Mara Dierssen, Willy Gsell, Neus Martinez-Abadias, Greetje Vande Velde

Summary: Using a mouse model of Down syndrome, we found that skull dysmorphologies occur before brain anomalies, and there is reduced integration and delayed acquisition of neurodevelopmental traits. Furthermore, we discovered that treatment affects the magnitude of integration and covariation patterns between the brain and skull.

FRONTIERS IN MEDICINE (2022)

Article Biochemistry & Molecular Biology

The X-linked splicing regulator MBNL3 has been co-opted to restrict placental growth in eutherians

Thomas Spruce, Mireya Plass, Andre Gohr, Debashish Ray, Maria Martinez de Lagran, Gregor Rot, Ana Novoa, Demian Burguera, Jon Permanyer, Marta Miret, Hong Zheng, Maurice S. Swanson, Quaid Morris, Moises Mallo, Mara Dierssen, Timothy R. Hughes, Barbara Pernaute, Manuel Irimia

Summary: Understanding the regulatory interactions that control gene expression during the development of novel tissues is a key goal of evolutionary developmental biology. Here, we show that Mbnl3 has evolved a novel placental function in eutherian mammals as a result of evolutionary specialization. Mbnl3 loss leads to increased placental growth and fetal resource allocation under limiting conditions.

PLOS BIOLOGY (2022)

Article Medicine, General & Internal

Muller glia fused with adult stem cells undergo neural differentiation in human retinal models

Sergi Angel Bonilla-Pons, Shoma Nakagawa, Elena Garreta Bahima, Alvaro Fernandez-Blanco, Martina Pesaresi, Justin Christopher D'Antin, Ruben Sebastian-Perez, Daniela Greco, Eduardo Dominguez-Sala, Raul Gomez-Riera, Rafael Ignacio Barraquer Compte, Mara Dierssen, Nuria Montserrat Pulido, Maria Pia Cosma

Summary: This study discovered that cell fusion can occur between human müller glia and adult stem cells in the human retina, resulting in partial regeneration of neurons. The results suggest that cell fusion-mediated therapy may be a potential regenerative approach for treating human retinal dystrophies.

EBIOMEDICINE (2022)

Article Immunology

COVID-19 Vaccination of Individuals with Down Syndrome-Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated

Anke Huls, Patrick T. Feany, Sophia Isabella Zisman, Alberto C. S. Costa, Mara Dierssen, Robert Balogh, Stefania Bargagna, Nicole T. Baumer, Ana Claudia Brandao, Angelo Carfi, Brian Allen Chicoine, Sujay Ghosh, Monica Lakhanpaul, Johannes Levin, Yona Lunsky, Coral Manso, Eitan Okun, Diego Real de Asua, Anne-Sophie Rebillat, Tilman R. Rohrer, Giuseppina Sgandurra, Diletta Valentini, Stephanie L. Sherman, Andre Strydom

Summary: Individuals with Down syndrome have a high uptake of COVID-19 vaccines with minimal side effects and breakthrough infections. Unvaccinated individuals were often younger, previously recovered from COVID-19, and not vaccinated against other recommended vaccines.

VACCINES (2022)

Article Genetics & Heredity

Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)

Cecile Cieuta-Walti, Aida Cuenca-Royo, Klaus Langohr, Claire Rakic, Ma Angeles Lopez-Vilchez, Julian Lirio, Domingo Gonzalez-Lamuno Leguina, Teresa Bermejo Gonzalez, Jordi Garcia Garcia, Maria Rimblas Roure, Ana Aldea-Perona, Laura Forcano, Maria Gomis-Gonzalez, Sebastia Videla Ces, Florence Lacaille, Aime Ravel, Clotilde Mircher, Herve Walti, Nathalie Janel, Julien Dairou, Marilyne Levy, Sophie Durand, Mara Dierssen, Silvia Sacco, Rafael de la Torre Fornell

Summary: This study evaluated the safety and tolerability of epigallocatechin gallate (EGCG) in children with Down syndrome (DS) and examined its effects on cognitive function and functionality. The results indicated that EGCG was safe and well-tolerated in children with DS, but did not show improvement in cognitive and functional performance.

GENETICS IN MEDICINE (2022)

Article Cell Biology

Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome

Maria Martinez de Lagran, Aleix Elizalde-Torrent, Roger Paredes, Bonaventura Clotet, Mara Dierssen

Summary: Elevated activity of retrotransposons is associated with various neurodegenerative and neurodevelopmental diseases. This study treated a mouse model of Down syndrome with a reverse transcriptase inhibitor and observed significant improvement in neurobehavioral phenotypes and complete recovery of hippocampal-dependent recognition memory.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2022)

Article Public, Environmental & Occupational Health

Differences in clinical presentation, severity, and treatment of COVID-19 among individuals with Down syndrome from India and high-income countries: Data from the Trisomy 21 Research Society survey

Halder Pinku, Anke Huls, Patrick T. Feany, Nicole Baumer, Mara Dierssen, Stefania Bargagna, Alberto Cs Costa, Brian A. Chicoine, Anne-Sophie Rebillat, Giuseppina Sgandurra, Diletta Valentini, R. Tilman Rohrer, Johannes Levin, Monica Lakhanpaul, Angelo Carfi, Stephanie L. Sherman, Andre Strydom, Sujay Ghosh

Summary: This study compares the clinical presentation, severity, and treatment differences of COVID-19 patients with Down syndrome (DS) between India and several high-income countries (HICs). The results show that patients from India are younger, have more comorbidities associated with severe COVID-19, and have higher hospitalization rates and COVID-19-related medical complications. Treatment strategies also differ, with more frequent use of antibiotics in India. The severity scores indicate that DS patients from India have more severe outcomes compared to European and US cases.

JOURNAL OF GLOBAL HEALTH (2022)

Review Neurosciences

Fluorescent transgenic mouse models for whole-brain imaging in health and disease

Adrian Arias, Linus Manubens-Gil, Mara Dierssen

Summary: A paradigm shift is occurring in neuroscience and life sciences, converting biomedical research into a quantitative and predictive science. New experimental tools and techniques allow for quantitative description and exploration of new features in living systems, with implications for understanding brain function and diseases.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2022)

Review Clinical Neurology

State-of-the-art therapy for Down syndrome

Nicola Lorenzon, Juanluis Musoles-Lleo, Federica Turrisi, Maria Gomis-Gonzalez, Rafael De La Torre, Mara Dierssen

Summary: In the last decade, efforts have been made to find new interventions for improving cognition in individuals with Down syndrome. However, the translation of specific findings into effective therapeutic strategies has been slow, leading to reduced credibility of mouse studies and failures at the clinical level.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2023)

Article Neurosciences

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

Mireia Ortega, Ilario De Toma, Alvaro Fernandez-Blanco, Anna Calderon, Lucia Barahona, Ramon Trullas, Eduard Sabido, Mara Dierssen

Summary: This study found that Dyrk1A overexpression affects oxidative phosphorylation and mitochondrial function in the cerebellum, and the EGCG in green tea extract can partially restore these changes.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2022)

Meeting Abstract Clinical Neurology

Epileptogenic network definition through game theory and connectivity dynamics

K. Ivankovic, A. Principe, J. Montoya, L. Manubens-Gil, M. Dierssen, R. Rocamora

EPILEPSIA (2022)

暂无数据